{"id":"adebrelimab-pd-l1-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Pneumonitis"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL4297828","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adebrelimab is a monoclonal antibody that binds to programmed death ligand 1 (PD-L1) on the surface of tumor cells and immune cells. By blocking the PD-L1/PD-1 interaction, it releases the brake on T cell-mediated anti-tumor immunity, enabling cytotoxic T lymphocytes to recognize and eliminate cancer cells. This mechanism is similar to other PD-L1 inhibitors and represents a form of immune checkpoint inhibition.","oneSentence":"Adebrelimab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:42.762Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT07392541","phase":"PHASE1, PHASE2","title":"Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-01-30","conditions":"Advanced Biliary Tract Carcinoma","enrollment":29},{"nctId":"NCT07434518","phase":"","title":"A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-01-27","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":500},{"nctId":"NCT06610734","phase":"PHASE2","title":"Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-12-23","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":202},{"nctId":"NCT07388095","phase":"NA","title":"Adebrelimab Neoadjuvant Treatment for Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-15","conditions":"ESCC","enrollment":22},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT07241793","phase":"PHASE2","title":"Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-20","conditions":"Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent","enrollment":96},{"nctId":"NCT07284992","phase":"PHASE2","title":"SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC","status":"RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2025-09-12","conditions":"Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy","enrollment":208},{"nctId":"NCT07281209","phase":"PHASE2","title":"A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-12","conditions":"NSCLC","enrollment":40},{"nctId":"NCT07238569","phase":"PHASE3","title":"Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-01","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer","enrollment":516},{"nctId":"NCT07230301","phase":"PHASE2","title":"Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions","status":"NOT_YET_RECRUITING","sponsor":"Sizhen Wang","startDate":"2025-11-30","conditions":"Pancreatic Cancer Metastatic","enrollment":20},{"nctId":"NCT07137858","phase":"PHASE2","title":"Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-15","conditions":"Oral Squamous Cell Carcinoma (OSCC), Neoadjuvant Chemoimmunotherapy","enrollment":70},{"nctId":"NCT07105592","phase":"PHASE1, PHASE2","title":"A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-05-13","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":68},{"nctId":"NCT07062328","phase":"PHASE2","title":"A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-10","conditions":"Biliary Tract Carcinoma","enrollment":39},{"nctId":"NCT07041437","phase":"PHASE2","title":"Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-30","conditions":"Advanced Breast Cancer","enrollment":48},{"nctId":"NCT06869239","phase":"","title":"Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-02-25","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","enrollment":65},{"nctId":"NCT06842472","phase":"PHASE2","title":"PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02","conditions":"Breast Cancer","enrollment":70},{"nctId":"NCT06775275","phase":"PHASE2","title":"A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2024-09-24","conditions":"Resectable Lung Non-Small Cell Carcinoma","enrollment":60},{"nctId":"NCT06470672","phase":"PHASE2","title":"Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-12","conditions":"Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","enrollment":32},{"nctId":"NCT06702566","phase":"NA","title":"The Effect of Serum Ferritin in irAE","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-04","conditions":"Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia","enrollment":1500},{"nctId":"NCT06700421","phase":"PHASE2","title":"Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wei Zhou","startDate":"2024-08-13","conditions":"Unresectable Locally Advanced Non-small Cell Lung Cancer","enrollment":32},{"nctId":"NCT06599775","phase":"PHASE2","title":"Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-10","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":42},{"nctId":"NCT04770207","phase":"PHASE2","title":"Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2020-11-01","conditions":"Hepatocellular Carcinoma, Solid Tumor, Adult","enrollment":100},{"nctId":"NCT06482788","phase":"PHASE2","title":"Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-05-22","conditions":"Esophagogastric Junction Adenocarcinoma","enrollment":26},{"nctId":"NCT06455410","phase":"PHASE2","title":"GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-06-18","conditions":"Nasopharyngeal Carcinoma","enrollment":216},{"nctId":"NCT06375317","phase":"PHASE2","title":"HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure","status":"NOT_YET_RECRUITING","sponsor":"Yehua Shen","startDate":"2024-04-30","conditions":"HCC - Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT06320301","phase":"PHASE2","title":"Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-01","conditions":"Biliary Tract Cancer, Gemox Chemotherapy","enrollment":43},{"nctId":"NCT06261125","phase":"PHASE2","title":"Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)","status":"RECRUITING","sponsor":"Mian XI","startDate":"2024-03-10","conditions":"Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT06236997","phase":"PHASE2","title":"Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-02-10","conditions":"Small Cell Lung Carcinoma","enrollment":48},{"nctId":"NCT06229067","phase":"PHASE2","title":"Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-19","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":182},{"nctId":"NCT06146985","phase":"PHASE2","title":"Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2023-12-01","conditions":"Thyroid Cancer","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SHR-A1316"],"phase":"phase_3","status":"active","brandName":"Adebrelimab (PD-L1 inhibitor)","genericName":"Adebrelimab (PD-L1 inhibitor)","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adebrelimab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer. Used for Non-small cell lung cancer (NSCLC), Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}